UBE2T peptides and vaccines containing the same
AssigneeOncotherapy Science, Inc.
InventorsTakuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
Life of this patent
Estimating the term…
Loading patent…
AssigneeOncotherapy Science, Inc.
InventorsTakuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
Estimating the term…
Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
A composition for inducing a CTL, wherein the composition comprises
A method for pulsing an HLA A-24 positive antigen presenting cell (APC) with a peptide, wherein the method comprises the step of contacting the APC with
A method for inducing a CTL, which recognizes a cell presenting a complex of an HLA-A24 antigen and a peptide, wherein the method comprises
Dependencies are inferred from the claim text.